Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Budesonide | CONCISE COMMENTARY

Concise Commentary: Budesonide—When Going Gluten-Free Is Not Good Enough

Author: Prashant Singh

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Excerpt

In this issue of Digestive Diseases and Sciences, Therrien et al. in a well-written, retrospective, observational study describe their experience with enteric-release budesonide in 42 patients with non-responsive celiac disease (NRCD) at two referral centers [1]. NRCD was defined as symptoms or signs suggestive of CD after at least 12 months of a gluten-free diet (GFD). They reported that 57% of the cohort had a clinical response to budesonide (i.e., patient-reported clinical improvement) and 66% of the responders had a complete clinical response (i.e., complete resolution of symptoms). …
Literature
1.
2.
Mukewar SS, Sharma A, Rubio-Tapia A, Wu TT, Jabri B, Murray JA. Open-capsule budesonide for refractory celiac disease. Am J Gastroenterol. 2017;112:959–967.CrossRef
Metadata
Title
Concise Commentary: Budesonide—When Going Gluten-Free Is Not Good Enough
Author
Prashant Singh
Publication date
01-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06514-w

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue

Original Article

Interactions Between Vitamin D and Calcium Intake, Vitamin D Receptor Genetic Polymorphisms, and Colorectal Cancer Risk

Original Article

Social Support Does Not Modify the Risk of Readmission for Patients with Decompensated Cirrhosis

EDITORIAL

Risk Assessment of Pancreatic Cysts: Benign and Malign Entwined

Review

An Update on the Management of Budd–Chiari Syndrome

Original Article

Differences Between Familial and Sporadic Celiac Disease

Original Article

Does Risk of Progression from Barrett’s Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits